Clinical Trial Detail

NCT ID NCT02287025
Title A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Out Comes?
Recruitment Terminated
Gender both
Phase FDA approved
Variant Requirements no
Sponsors Bayer
Indications

colorectal cancer

Therapies

Regorafenib

Age Groups: adult

No variant requirements are available.